Robert Gabbay, MD, PhD, of the American Diabetes Association, explains why a section on chronic kidney disease management was added to the ADA's 2022 standard of care guidelines.
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), explains why a section on chronic kidney disease (CKD) management was added to the ADA's 2022 standard of care guidelines.
Transcript:
What evidence led to the addition of Section 11 in the ADA’s 2022 guidelines?
Gabbay: [A couple] of the things that became clear based on some of the recent studies and new treatments that are available are a couple of things. One, we know that chronic kidney disease continues to be a huge issue and it's under-diagnosed and under-treated. And second, we now have new treatments that can really lower the risk of chronic kidney disease, and particularly the progression. So, we called out all of that information by making chronic kidney disease a separate section [of the guidelines] to emphasize the importance of it.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More